Form 4: Aura Biosciences Director Bitetti Receives Stock and Options

Director Teresa Marie Bitetti acquired 21,000 shares of common stock and options for 29,000 shares of Aura Biosciences, Inc.

Summary

• On March 31, 2025, Teresa Marie Bitetti, a director of Aura Biosciences, Inc., acquired 21,000 shares of common stock through a restricted stock unit (RSU) award.
• The RSUs vest in three substantially equal annual installments beginning on April 15, 2026, contingent upon continued service.
• Bitetti also acquired options for 29,000 shares of common stock at an exercise price of $5.86.
• These options vest in three substantially equal annual installments beginning on March 31, 2026, also subject to continued service.
• Following these transactions, Bitetti directly owns 21,000 shares of common stock and options for 29,000 shares.

Sentiment

Score: 7

Explanation: The document reflects a standard practice of incentivizing a director with stock and options, suggesting a positive outlook on the company's future. The vesting schedules indicate a long-term commitment.

Positives

• The acquisition of stock and options by a director signals confidence in the company's future.
• The vesting schedules tied to continued service align the director's interests with the long-term success of the company.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedules suggest an expectation of continued service and commitment from the director.

Industry Context

This type of stock and option grant is a common practice in the biotechnology industry to incentivize and retain key personnel, aligning their interests with the company's long-term performance.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation practices in the biotech industry.
• Vesting schedules of three years are also typical to ensure long-term commitment.
• Comparable companies often use similar equity-based compensation to attract and retain talent.

Stakeholder Impact

• Shareholders may view the stock and option grants positively, as they align the director's interests with the company's performance.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

Aura Biosciences, Director, Stock Options, RSU, Beneficial Ownership, Form 4, Bitetti, Vesting